[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Neurocrine Biosciences, Inc. (NBIX)
Neurocrine Biosciences hits a 52-week high driven by strong INGREZZA sales, despite a slight EPS miss. Analysts are raising price targets, signaling positive sentiment for the biopharmaceutical company.
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on treatments for neurological and endocrine-related disorders.
Neurocrine Biosciences, Inc. uses the ticker $NBIX for trading. Listed in the Stocks category within the Healthcare sectors.
Insights
- Neurocrine Biosciences, Inc. (NBIX) trading volume is up XXXXX% from the previous week.
- Neurocrine Biosciences, Inc. (NBIX) social dominance is up XXXXXX% from the previous X months.
- Neurocrine Biosciences, Inc. (NBIX) Galaxy Score™ is up XXXXX% from the previous week.
- Neurocrine Biosciences, Inc. (NBIX) engagements is up XXXX% from the previous week.
- Neurocrine Biosciences, Inc. Price hit a 52-Week high of $XXXXXX for the hour
- Neurocrine Biosciences, Inc. Price hit an all time of $XXXXXX for the hour
Price: $XXXXXX
Price 24-Hour Time-Series Raw Data
The stock price recently hit a 52-week high, driven by strong Q3 results and record INGREZZA sales. While missed EPS estimates introduced some minor downward pressure, the overall sentiment remains positive due to strong product performance and successful launches, with analysts raising price targets.
24-Hour: -XXXX% 7-Day: -XXXX% 30-Day: XXXX%
1-Year High: $XXXXXX on 2025-12-10
1-Year Low: $XXXXX on 2025-04-08
AltRank: XXXXX
AltRank 24-Hour Time-Series Raw Data
Neurocrine Biosciences, Inc. (NBIX) is currently AltRank #1,274 based on combined combined social and market metrics
Daily Average: XXX
X Week: XXXXX +754
X Month: XXXXX +320
X Months: XXXXX +276
X Year: XXXXX +908
1-Year High: XXXXX on 2025-09-25
1-Year Low: XX on 2025-05-06
Galaxy Score: XXXXX
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XX
X Week: XX +11
X Month: XX -X
X Months: XX -XX
X Year: XX -XX
1-Year High: XX on 2025-01-13
1-Year Low: X on 2025-09-24
Engagements: XXX (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: XXX
Daily Average: XXXXXX
X Week: XXXXX +12%
X Month: XXXXXX -XX%
X Months: XXXXXXXXX +19%
X Year: XXXXXXXXX +13%
1-Year High: XXXXXXX on 2025-05-05
1-Year Low: XXX on 2025-12-06
Engagements by network (24h): Reddit: X X: XXX YouTube: X
Mentions: XX (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XXX
X Week: XXX -XX%
X Month: XXX -XX%
X Months: XXXXXX +441%
X Year: XXXXXX +329%
1-Year High: XXXXX on 2025-07-03
1-Year Low: XX on 2025-12-07
Mentions by network (24h): Reddit: X X: XXX YouTube: X
Creators: XX (24h)
Creators 24-Hour Time-Series Raw Data
XX unique social accounts have posts mentioning Neurocrine Biosciences, Inc. (NBIX) in the last XX hours which is up XX% from XX in the previous XX hours
Daily Average: XXX
X Week: XX -XX%
X Month: XXX -XX%
X Months: XXXXX +1,139%
X Year: XXXXXX +829%
1-Year High: XXXXX on 2025-07-03
1-Year Low: XX on 2025-12-07
The most influential creators that mention Neurocrine Biosciences, Inc. in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @Andre_AGTC | X | XXXXX | X | XXX |
| @Biobeats99 | X | XXX | X | XX |
| @NightOwlBiotech | X | XXXXX | X | XX |
| @BuyTheUgly | X | XX | X | XX |
| @doepke_michel | X | XXXXX | X | XX |
| @MarcJacksonLA | X | XXXXX | X | X |
Sentiment: XX%
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
X Week: XX% -XX%
X Month: XX% -XX%
X Months: XX% -XX%
X Year: XX% -X%
1-Year High: XXX% on 2025-07-20
1-Year Low: XX% on 2025-09-13
Most Supportive Themes:
- Ingrezza Sales Growth: (40%) Ingrezza sales are increasing market penetration and revenue.
- Crenessity Phase X Study: (35%) Positive outcomes from the Crenessity Phase X study boost confidence in Neurocrine's pipeline.
- Affordable Growth Potential: (25%) Mentions in 'Affordable Growth' screens highlight the potential for long-term value.
Most Critical Themes:
- Missed EPS Estimates: (5%) Missed EPS estimates may cause short-term volatility.
Social Dominance: XXXXXXX%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXXX%
Daily Average: XXXXX%
X Week: XXXXX% +0.0023%
X Month: XXXXXX% +0.0013%
X Months: XXXXXX% -XXXXXX%
X Year: XXXXXX% -XXXXX%
1-Year High: XXXXX% on 2025-07-03
1-Year Low: XXXXXX% on 2025-12-07
Market Dominance: XXXXX%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXX%
Daily Average: X%
1-Year High: XXXXX% on 2025-12-02
1-Year Low: XXXXX% on 2025-03-19
Market Cap: $XXXXXXXXXXXXXX
Market Cap 24-Hour Time-Series Raw Data
Current Value: $XXXXXXXXXXXXXX
Daily Average: $XXXXXXXXXXXXXX
X Week: $XXXXXXXXXXXXXX -$1.70%
X Month: $XXXXXXXXXXXXXX +$6%
X Months: $XXXXXXXXXXXXXX +$23%
X Year: $XXXXXXXXXXXXXX +$19%
1-Year High: $XXXXXXXXXXXXXX on 2025-01-30
1-Year Low: $XXXXXXXXXXXXX on 2025-04-12
Top Neurocrine Biosciences, Inc. Social Posts
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"@BiotechAnalysst Not a rating note but @Official_Cantor s BBB report gives $SGMO outsized attention as a validated BBB-crossing AAV platform placed alongside CNS delivery leaders like $VYGR $DNLI and $NBIX. That kind of positioning is rarely accidental. @SangamoTx @cantorfitzgerld"
X Link @ZinselmeyerB 2025-12-13T15:47Z XXX followers, XXX engagements
"Jefferies Recap of the American Epilepsy Society (AES) 2025 annual meeting highlights key clinical data and development updates across multiple companies in the neurology space. Full report in Bio $PRAX $XENE $STOK $RAPP $UCB $ENCD $AXSM $SAGE $ACAD $BIIB $NBIX $SUPN"
X Link @Biobeats99 2025-12-11T16:18Z XXX followers, XXX engagements
".@GibbsErin tells @DianeKingHall that 2026 will be the year for small- and mid-cap stocks. She explains why the outlook for 2026 is different from past bullish expectations. Her top picks include Krystal Biotech $KRYS; Exelixis $EXEL; and Neurocrine $NBIX. For more:"
X Link @SchwabNetwork 2025-12-10T15:08Z 76.8K followers, 2203 engagements
"Big fan of @GibbsErin who brought her outlook for 2026. Expect to see stronger growth in SMIDs beyond SPX. Individual picks she likes: $KRYS $EXEL $NBIX"
X Link @DianeKingHall 2025-12-10T14:20Z 5983 followers, XXX engagements